IRIX (IRIDEX) Total Operating Expense: $21.60 Mil (TTM As of Mar. 2026)


IRIX IRIDEX Corp IRIX
66 GF Score
Price $1.17
GF Value $1.70
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is IRIDEX Total Operating Expense?

IRIDEX IRIX -4.24% 66 Total Operating Expense is $21.60 Mil as of Mar. 2026. GuruFocus rates IRIX with a GF Score™ of 66/100 and a GF Value™ of $1.70 (Possible Value Trap). The stock has 3 warning signs investors should review.

IRIDEX's Total Operating Expense for the three months ended in Mar. 2026 was $5.07 Mil. IRIDEX's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $21.60 Mil.

IRIDEX Total Operating Expense Related Terms

IRIDEX Total Operating Expense Historical Data

* Premium members only.

The historical data trend for IRIDEX's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRIDEX Total Operating Expense Chart

IRIDEX Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.36 32.91 31.81 27.80 21.80

IRIDEX Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.26 5.62 5.42 5.49 5.07
IRIX
66GF Score
IRIDEX Corp IRIX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IRIDEX Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $21.60 Mil mean?
IRIDEX (IRIX) has a Total Operating Expense of $21.60 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on IRIDEX and its competitors.
Is IRIDEX's Total Operating Expense too high?
IRIDEX's current Total Operating Expense is $21.60 Mil. Overall, IRIDEX has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRIDEX's Total Operating Expense compare to ICCM and ADGM?
IRIDEX's Total Operating Expense of $21.60 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Devices & Instruments company?
A good Total Operating Expense depends on the Medical Devices & Instruments industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on IRIDEX and its competitors. IRIDEX's current Total Operating Expense is $21.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRIDEX stock overvalued right now?
Based on GuruFocus' analysis, IRIDEX (IRIX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.70, compared to a current price of $1.17 — trading 31.2% below its estimated fair value. The current Total Operating Expense is $21.60 Mil. IRIDEX's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For IRIDEX (IRIX), the current Total Operating Expense is $21.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IRIDEX (IRIX) Overvalued in 2026?

Based on GuruFocus' analysis, IRIDEX stock appears to be undervalued. The current stock price of $1.17 is trading 31.2% below its estimated GF Value™ of $1.70. GuruFocus considers IRIDEX to be Possible Value Trap.

Key valuation signals for IRIX:

  • Total Operating Expense: $21.60 Mil
  • GF Value™: $1.70 vs. price of $1.17 (31.2% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the IRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRIDEX Business Description

Address 1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
66GF Score

Get the complete analysis for IRIX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.17
Price
$1.70
GF Value